Thyrocare Technologies Ltd
NSE:THYROCARE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
559.95
985.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Thyrocare Technologies Ltd
Thyrocare Technologies Ltd
Total Equity
Thyrocare Technologies Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Total Equity
₹5.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Total Equity
₹1.6B
|
CAGR 3-Years
42%
|
CAGR 5-Years
28%
|
CAGR 10-Years
24%
|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Total Equity
₹20B
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Total Equity
₹5.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Total Equity
₹8.1B
|
CAGR 3-Years
52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Total Equity
₹11B
|
CAGR 3-Years
16%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
What is Thyrocare Technologies Ltd's Total Equity?
Total Equity
5.3B
INR
Based on the financial report for Jun 30, 2024, Thyrocare Technologies Ltd's Total Equity amounts to 5.3B INR.
What is Thyrocare Technologies Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
4%
Over the last year, the Total Equity growth was -1%. The average annual Total Equity growth rates for Thyrocare Technologies Ltd have been 7% over the past three years , 4% over the past five years .
You don't have any saved screeners yet
